Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Applying to Memorial Sloan-Kettering Cancer Center · New York, New York
Answer a few short questions to share with the research team.